Prescription Patterns of Novel Antihyperglycemic Medications

References

1. 1.↵
   American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S125–S150.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021;44:S111–S124. Jan.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Low Wang CC,
   2. Everett BM,
   3. Burman KD,
   4. Wilson PWF

   . Cardiovascular safety trials for all new diabetes mellitus drugs? Circulation 2019;139:1741–3. Apr 2.

   OpenUrl
4. 4.↵
   1. Marso SP,
   2. Daniels GH,
   3. Brown-Frandsen K,
   4. et al

   . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22. Jul 28.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Marso SP,
   2. Bain SC,
   3. Consoli A,
   4. et al

   . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. Nov 10.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Zinman B,
   2. Wanner C,
   3. Lachin JM

   , EMPA-REG OUTCOME Investigatorset al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. Nov 26.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Neal B,
   2. Perkovic V,
   3. Mahaffey KW,
   4. et al

   . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. Aug 17.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Drucker DJ,
   2. Sherman SI,
   3. Gorelick FS,
   4. Bergenstal RM,
   5. Sherwin RS,
   6. Buse JB

   . Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428–33. Feb.

   OpenUrlFREE Full Text
9. 9.↵
   1. Rotz ME,
   2. Ganetsky VS,
   3. Sen S,
   4. Thomas TF

   . Implications of incretin-based therapies on cardiovascular disease. Int J Clin Pract 2015;69:531–49. May.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Monami M,
    2. Marchionni N,
    3. Mannucci E

    . Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009;160:909–17.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Monami M,
    2. Cremasco F,
    3. Lamanna C,
    4. et al

    . Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Gamble JM,
    2. Thomas JM,
    3. Twells LK,
    4. Midodzi WK,
    5. Majumdar SR

    . Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine (Baltimore) 2016;95:e3995.

    OpenUrl
13. 13.↵
    1. Kristensen SL,
    2. Rorth R,
    3. Jhund PS,
    4. et al

    . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776–85.

    OpenUrlPubMed
14. 14.↵
    1. Morris ZS,
    2. Wooding S,
    3. Grant J

    . The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 2011;104:510–20.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Lenfant C

    . Shattuck lecture–clinical research to clinical practice–lost in translation? N Engl J Med 2003;349:868–74.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Anderson TS,
    2. Lo-Ciganic WH,
    3. Gellad WF,
    4. et al

    . Patterns and predictors of physician adoption of new cardiovascular drugs. Healthc (Amst) 2018;6:33–40.

    OpenUrl
17. 17.↵
    1. Zhang Y,
    2. Mendez SJ,
    3. Scott A

    . Factors affecting general practitioners' decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data. BMC Health Serv Res 2019;19:94.

    OpenUrl
18. 18.↵
    1. Ailawadhi S,
    2. Frank RD,
    3. Advani P,
    4. et al

    . Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med 2017;6:2876–85.

    OpenUrl
19. 19.↵
    1. Schore J,
    2. Brown R,
    3. Lavin B

    . Racial disparities in prescription drug use among dually eligible beneficiaries. Health Care Financ Rev 2003;25:77–90.

    OpenUrlPubMed
20. 20.↵
    1. Montvida O,
    2. Shaw J,
    3. Atherton JJ,
    4. Stringer F,
    5. Paul SK

    . Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 2018;41:69–78.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    Centers for Disease Control and Prevention. United States Diabetes Surveillence System. `Updated April 2021. Accessed July 29, 2021. https://gis.cdc.gov/grasp/diabetes/diabetesatlas.html#.
22. 22.↵
    United States Census Bureau. Age and sex: American community survey (ACS 1-year estimates subject tables). United States Census Bureau. Updated July 2021. Accessed July 29, 2021. https://data.census.gov/cedsci/table?q=Age&g=0100000US&tid=ACSST1Y2016.S0101&hidePreview=false.
23. 23.↵
    1. Palmer SC,
    2. Tendal B,
    3. Mustafa RA,
    4. et al

    . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 01 13;372:m4573.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    United States Census Bureau. Demographic and housing estimates: American community survey (2016 - ACS 1 year estimates data profiles). US Census Bureau. Updated July 2021. Accessed July 29, 2021. https://data.census.gov/cedsci/table?q=Race&g=0100000US&tid=ACSDP1Y2016.DP05&hidePreview=false.
25. 25.↵
    1. Mishriky BM,
    2. Powell JR,
    3. Wittwer JA,
    4. et al

    . Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab 2019;21:2274–83.

    OpenUrl
26. 26.↵
    1. Shomali ME,
    2. Orsted DD,
    3. Cannon AJ

    . Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials. Diabet Med 2017;34:197–203.

    OpenUrl
27. 27.↵
    Bureau USC. Income in the past 12 months (in 2016 inflation-adjusted dollars). American Community Survey 1-year estimates. https://data.census.gov/cedsci/table?q=Income%20Wayne%20County,%20Michigan&g=0500000US26099,26125&tid=ACSST1Y2016.S1901&hidePreview=true.